Non‐invasive metabolic biomarkers in initial cognitive impairment in patients with diabetes: A systematic review and meta‐analysis
Authors' conclusion
Our results suggest that MI, Glu, and Glx concentrations and NAA/Cr ratios within the hippocampus may serve as metabolic biomarkers for patients with early-stage DCI.
Study context
- Population
- Patients with diabetes with early cognitive impairment; PubMed, Embase, Web of Science and Cochrane searched up to March 2024
- Participants
- 4,357 patients13 clinical studies
- Comparison
- Diabetic cognitive impairment (DCI) vs control
- Outcome
- Dysregulated metabolites as potential biomarkers for early DCI
Methodological detailsqualitative review, subgroup and sensitivity analyses
- Qualitative review
- Subgroup and sensitivity analyses
Pooled result
As reported in the abstract
Brain metabolites (six metabolites, two ratios)
- Significant increase in myo-inositol (MI) concentration in DCI
- Decreases in glutamate (Glu), Glx (glutamate and glutamine) and NAA/Cr ratios in DCI
Further pooled results
Diabetes type and brain region
- Brain metabolic changes with cognitive impairment more pronounced in T2D than T1D
- Hippocampus the most sensitive brain region for DCI-associated metabolic changes
Original publication
Non‐invasive metabolic biomarkers in initial cognitive impairment in patients with diabetes: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 4 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →